Sei Investments Co. grew its stake in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 56.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,395,794 shares of the biopharmaceutical company’s stock after purchasing an additional 505,624 shares during the period. Sei Investments Co. owned approximately 0.64% of Insmed worth $228,239,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. grew its stake in Insmed by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock valued at $3,668,127,000 after acquiring an additional 1,140,524 shares during the last quarter. Darwin Global Management Ltd. lifted its stake in shares of Insmed by 2.3% during the 4th quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock worth $3,644,274,000 after purchasing an additional 475,832 shares during the period. State Street Corp boosted its holdings in shares of Insmed by 30.6% during the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock worth $905,312,000 after purchasing an additional 1,217,390 shares during the last quarter. RTW Investments LP boosted its holdings in shares of Insmed by 57.0% during the fourth quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock worth $842,855,000 after purchasing an additional 1,758,321 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Insmed by 14.4% during the fourth quarter. Geode Capital Management LLC now owns 4,299,052 shares of the biopharmaceutical company’s stock worth $751,936,000 after purchasing an additional 539,625 shares during the last quarter.
Insider Transactions at Insmed
In related news, COO Roger Adsett sold 2,370 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $242,379.90. Following the sale, the chief operating officer owned 98,603 shares of the company’s stock, valued at approximately $10,084,128.81. This trade represents a 2.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Michael Alexander Smith sold 1,806 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $95.82, for a total value of $173,050.92. Following the transaction, the insider owned 37,648 shares of the company’s stock, valued at $3,607,431.36. This represents a 4.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 54,590 shares of company stock valued at $5,793,738. 2.10% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on Insmed
Insmed Stock Down 1.8%
Shares of Insmed stock opened at $106.64 on Thursday. Insmed, Inc. has a twelve month low of $90.39 and a twelve month high of $212.75. The stock has a market cap of $23.11 billion, a price-to-earnings ratio of -18.55 and a beta of 0.78. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The company has a fifty day moving average price of $105.41 and a 200 day moving average price of $134.22.
Insmed (NASDAQ:INSM – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. During the same period last year, the company posted ($1.42) earnings per share. The firm’s revenue was up 229.7% compared to the same quarter last year. Equities research analysts forecast that Insmed, Inc. will post -2.43 earnings per share for the current fiscal year.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
See Also
- Five stocks we like better than Insmed
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM – Free Report).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
